Comparative Pharmacology
Head-to-head clinical analysis: LAMPIT versus NEBUPENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMPIT versus NEBUPENT.
LAMPIT vs NEBUPENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the enzyme G6PD (glucose-6-phosphate dehydrogenase) in Trypanosoma cruzi, leading to oxidative stress and parasite death.
Nebupent (pentamidine isethionate) is an antimicrobial agent that inhibits the synthesis of DNA, RNA, phospholipids, and proteins in protozoa. Its mechanism may involve interference with polyamine synthesis and inhibition of dihydrofolate reductase.
Nifurtimox (Lampit) for Chagas disease: adult dose 8-10 mg/kg/day orally in 3 divided doses for 90 days. For Chagas disease in children: 15-20 mg/kg/day orally in 3 divided doses for 90 days.
300 mg via inhalation once every 4 weeks for prophylaxis of Pneumocystis jirovecii pneumonia.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours. In hepatic impairment, half-life may be prolonged by up to 2-fold.
Terminal elimination half-life: 6-9 hours (prolonged in renal impairment; clinical context: supports once-daily dosing for treatment, but prophylaxis may require reduced frequency in renal dysfunction)
Renal excretion of unchanged drug accounts for 10% of the dose; biliary/fecal excretion accounts for approximately 90%, mainly as metabolites.
Renal: approximately 90% as unchanged drug; biliary/fecal: minimal (<5%)
Category C
Category C
Antiprotozoal
Antiprotozoal, Inhaled